[HTML][HTML] Preclinical cancer models and biomarkers for drug development: new technologies and emerging tools

M Dhandapani, A Goldman - Journal of molecular biomarkers & …, 2017 - ncbi.nlm.nih.gov
Background and purpose Predicting the efficacy of anticancer therapy is the holy grail of
drug development and treatment selection in the clinic. To achieve this goal, scientists …

[PDF][PDF] Preclinical Cancer Models and Biomarkers for Drug Development: New Technologies and Emerging Tools

M Dhandapani, A Goldman - J Mol Biomark Diagn. Author …, 2017 - pdfs.semanticscholar.org
Background and purpose—Predicting the efficacy of anticancer therapy is the holy grail of
drug development and treatment selection in the clinic. To achieve this goal, scientists …

Preclinical Cancer Models and Biomarkers for Drug Development: New Technologies and Emerging Tools

M Dhandapani, A Goldman - Journal of molecular biomarkers & …, 2017 - dash.harvard.edu
Background and purpose Predicting the efficacy of anticancer therapy is the holy grail of
drug development and treatment selection in the clinic. To achieve this goal, scientists …

Preclinical Cancer Models and Biomarkers for Drug Development: New Technologies and Emerging Tools

M Dhandapani, A Goldman - Journal of molecular …, 2017 - pubmed.ncbi.nlm.nih.gov
Background and purpose Predicting the efficacy of anticancer therapy is the holy grail of
drug development and treatment selection in the clinic. To achieve this goal, scientists …

Preclinical Cancer Models and Biomarkers for Drug Development: New Technologies and Emerging Tools.

M Dhandapani, A Goldman - Journal of Molecular Biomarkers & …, 2017 - europepmc.org
Background and purpose Predicting the efficacy of anticancer therapy is the holy grail of
drug development and treatment selection in the clinic. To achieve this goal, scientists …